Patients suffering from vitiligo, an autoimmune disease that causes progressive depigmentation of the skin, will benefit from the first official treatment reimbursed by health insurance, according to a decree published Wednesday in the Official Journal.
This treatment concerns Opzelura cream, developed by the American laboratory Insight Biosciences, for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents over 12 years of age. It intervenes within the framework of the so-called “direct access” system, an experimental measure included in the social security financing law from 2022 so that certain medicines reach French patients more quickly.
About 1 to 2% of the world’s population is affected
Vitiligo causes progressive breakdown of the skin’s pigment-producing cells (melanocytes) leading to depigmentation in the form of white patches on the face and body.
The French Vitiligo Association estimates that around 1 to 2% of the world’s population is affected by this highly visible chronic disease that can lead to “significant changes in quality of life, relationships with others and with oneself”. According to Insight Biosciences, which employs 2,500 staff, including 50 in France, more than a million people in France are affected by this pathology.
Opzelura received a valid marketing authorization throughout the European Union in April. In October, the High Authority of Health issued a favorable opinion for its reimbursement. The pharmaceutical company then requested the Ministry of Health for direct access, i.e. without waiting for price negotiations. Opzelura treatment is already available in the United States, Germany and Austria.
During the direct access period “the patient will have to receive the treatment in the hospital pharmacy”, the manufacturer’s spokeswoman in France, Claire Lherito-Calme, indicated. By applying the cream twice a day, “the patient will gradually see repigmentation,” she added, referring to the results of a phase III study that ultimately showed improvement in the face. Six months of treatment for about 31% of patients. In December, a treatment for hemophilia B, marketed by CSL Behring Laboratories under the name Hemgenix, was the first indication of direct access coverage in France.
